Trv Gp Vi LLC Has $24.39 Million Position in Septerna, Inc. (NASDAQ:SEPN)

Key Points

• Trv Gp Vi LLC has increased its stake in Septerna, Inc. by 33.6%, now holding approximately 9.46% of the company valued at about $24.39 million.
• Septerna reported a quarterly earnings loss of ($0.49) EPS, below the consensus estimate of ($0.38), and forecasts suggest an annual EPS of -7.11.
• Analysts have set a new average target price of $26.75 for Septerna, with several firms recently upgrading their ratings and target prices significantly.

Trv Gp Vi LLC raised its stake in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) by 33.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,211,659 shares of the company's stock after acquiring an additional 1,059,203 shares during the quarter. Septerna makes up about 58.1% of Trv Gp Vi LLC's portfolio, making the stock its biggest position. Trv Gp Vi LLC owned approximately 9.46% of Septerna worth $24,386,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in shares of Septerna during the 4th quarter worth $160,205,000. TRV GP V LLC bought a new position in Septerna in the fourth quarter worth about $142,337,000. Samsara BioCapital LLC purchased a new stake in shares of Septerna during the fourth quarter valued at about $63,399,000. Driehaus Capital Management LLC bought a new stake in shares of Septerna in the 4th quarter valued at about $59,301,000. Finally, BVF Inc. IL purchased a new position in shares of Septerna in the 4th quarter worth approximately $56,151,000.

Septerna Price Performance

NASDAQ:SEPN opened at $11.75 on Thursday. Septerna, Inc. has a twelve month low of $4.17 and a twelve month high of $28.99. The company's 50 day moving average is $11.30 and its two-hundred day moving average is $9.50.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter. As a group, research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SEPN shares. Wells Fargo & Company increased their target price on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research report on Friday, May 16th. HC Wainwright initiated coverage on Septerna in a report on Monday, June 23rd. They set a "buy" rating and a $26.00 price objective for the company. Finally, Cantor Fitzgerald raised their price objective on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Septerna has an average rating of "Moderate Buy" and an average target price of $26.75.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.